ArticlePharmaceuticals (Basel, Switzerland)2022

ATL I, Acts as a SIRT6 Activator to Alleviate Hepatic Steatosis in Mice via Suppression of NLRP3 Inflammasome Formation.

Danli Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.